David Alan Campbell, President and CEO at Janux Therapeutics, Inc. (JANX), sold 49,205 shares at $46.09 ($2.3M) on 2024-09-27, disclosed to the SEC on 2024-09-27.
Scheduled sale ($2.3M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.09 | 18,957 | $874K | 38.4% |
| 2 | $46.09 | 18,957 | $874K | 38.4% |
| 3 | $46.86 | 5,248 | $246K | 10.8% |
| 4 | $46.86 | 5,248 | $246K | 10.8% |
| 5 | $47.84 | 795 | $38K | 1.7% |
| Total | $46.28 avg | 49,205 |
| $2.3M |
| 100% |
| Filing → |
| JANX | SELL | 2024-12-27 | $1.4M | — | Filing → |
| JANX | SELL | 2024-12-03 | $1.0M | — | Filing → |
| JANX | SELL | 2024-11-27 | $2.6M | — | Filing → |